MoonLake Immunotherapeutics - Ordinary Shares - Class A
MLTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.41B
Close$
$4.01
78% downside
Current Fair Value
78% downsideOvervalued by 78% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.41 Billion |
|---|---|
| Enterprise Value | $1.21 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.53 |
| Beta | 1.01 |
| Outstanding Shares | 71,273,650 |
Return
| Return on Equity | -101.49% |
|---|---|
| Return on Assets | -64.39% |
| Return on Invested Capital | -52.14% |
Valuation & Multiples
| P/E Ratio | -5.32 |
|---|---|
| PEG | -7.27 |
| Price to Sales | - |
| Price to Book Ratio | 6.09 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.57 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.93
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2499▼ 10.82% |
|---|---|
| Total Calls | 1,570,200▼ 39.71% |
| Total Puts | 392,400▼ 57.92% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.80%▲ 8.87% |
|---|---|
| Total Invested | $1.17B▲ 57.94% |
| Investors Holding | 158▲ 13.00% |
ESG Score
No data